Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by Zacks Research

Key Points

• Zacks Research upgraded Prestige Consumer Healthcare from “hold” to “strong buy,” although Weiss Ratings maintained a “sell (D+)” rating. The overall analyst consensus remains “hold,” with a target price of $67.67.
• Prestige Consumer Healthcare shares opened at $44.68, near their 52-week low of $42.62 and below both their 50-day and 200-day moving averages.
• The company exceeded quarterly expectations, reporting $0.98 in EPS versus $0.89 expected and $265.71 million in revenue versus $253.02 million expected; revenue increased 6.5% year over year.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research note issued to investors on Wednesday, Zacks reports.

Separately, Weiss Ratings reiterated a "sell (d+)" rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $67.67.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $44.68 on Wednesday. The business has a fifty day simple moving average of $50.06 and a 200-day simple moving average of $51.33. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $71.07. The company has a market cap of $2.12 billion, a P/E ratio of 12.51, a P/E/G ratio of 1.44 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The company had revenue of $265.71 million during the quarter, compared to analysts' expectations of $253.02 million. During the same period in the previous year, the company earned $0.90 EPS. The business's quarterly revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Equities research analysts forecast that Prestige Consumer Healthcare will post 4.56 EPS for the current year.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the business. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth $30,000. Versant Capital Management Inc raised its holdings in Prestige Consumer Healthcare by 47.9% in the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company's stock valued at $34,000 after acquiring an additional 235 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock worth $35,000 after purchasing an additional 236 shares during the period. Cornerstone Planning Group LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 1st quarter valued at about $44,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at approximately $80,000. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc NYSE: PBH is a consumer healthcare company that develops, markets and distributes over-the-counter (OTC) products and household health-care brands. Its portfolio includes products for eye care, oral care, gastrointestinal health, pain relief, respiratory health, women's health, and other everyday health needs.

The company's brands include Dramamine, Bonine, BC, Goody's, Clear Eyes, TheraTears, Monistat, Summer's Eve, Vagisil, Luden's, Chloraseptic, Compound W, Fleet and Debrox.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.